Z-521

Phase 3Small molecule

ZZeria Pharmaceutical

Z-521 is one of 6 small molecule programs targeting Hypophosphatemic Rickets. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypophosphatemic RicketsActive, not recruiting

Hypophosphatemic RicketsPhase 3

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Hypophosphatemic Rickets

#DrugCompanyPhaseTrials

Calciferol

Alnylam Pharmaceuticals

Approved

—2

Rocaltrol

Alnylam Pharmaceuticals

Approved

—3

CRYSVITA

Kyowa Kirin Co., Ltd.

Phase 3

1 4

Sensipar

Amgen

Phase 1

2 5

Z-521

ZZeria Pharmaceutical

Phase 3

1 6

Renagel

GGenzyme, a Sanofi Company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypophosphatemic Rickets1 trial

Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets

Completed·ZZeria Pharmaceutical·Phase 3·NCT01237288·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Z-521. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Z-521 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Z-521. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zeria Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZeria Pharmaceutical

Z-521

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypophosphatemic Rickets1 trial

References

Drug Info

Quick Facts

Related News